Thera-SAbDab

NARSOPLIMAB

>   Structural Summary
TherapeuticNarsoplimab
TargetMASP2
Heavy ChainQVTLKESGPVLVKPTETLTLTCTVSGFSLSRGKMGVSWIRQPPGKALEWLAHIFSSDEKSYRTSLKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIRRGGIDYWGQGTLVTVSS
Light ChainQPVLTQPPSLSVSPGQTASITCSGEKLGDKYAYWYQQKPGQSPVLVMYQDKQRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLTVL
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Preregistration
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2019
INN Year Recommended2020
Companies InvolvedOmeros
Conditions Approvedna
Conditions ActiveHaemolytic uraemic syndrome, IgA nephropathy, Immediate hypersensitivity, Thrombotic microangiopathies, Glomerulonephritis, Lupus nephritis, Membranous glomerulonephritis
Conditions DiscontinuedStroke, Wet age-related macular degeneration
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]